AR113811A1 - Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos - Google Patents
Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismosInfo
- Publication number
- AR113811A1 AR113811A1 ARP180103157A ARP180103157A AR113811A1 AR 113811 A1 AR113811 A1 AR 113811A1 AR P180103157 A ARP180103157 A AR P180103157A AR P180103157 A ARP180103157 A AR P180103157A AR 113811 A1 AR113811 A1 AR 113811A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- alkyl
- cycloalkyl
- membered
- group
- Prior art date
Links
- 150000003457 sulfones Chemical class 0.000 title 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- -1 C(O)alquilo C1−6 Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004001 thioalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde R¹ se selecciona del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₆, CH₂-(cicloalquilo C₃₋₆), alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, alquil C₁₋₆-N(RN)₂, fenilo, bencilo, heterociclilo de 4 a 8 miembros y heteroarilo de 5 a 6 miembros; y en donde R¹ está opcionalmente sustituido por uno o dos sustituyentes cada uno independientemente seleccionado del grupo que consiste en halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, alquil C₁₋₆-N(RN)₂, hidroxilo, hidroxialquilo C₁₋₆, ciano, cianoalquilo C₁₋₆, C₍O₎ₐₗqᵘⁱₗₒ C₁₋₆, fenilo, bencilo, CH₂-(cicloalquilo C₃₋₆), heteroarilo de 5 a 6 miembros, y CH₂-(heteroarilo de 5 a 6 miembros); n es 0, 1 ó 2; cada R² se selecciona independientemente del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆ y haloalquilo C₁₋₆; o dos R² junto con el átomo de nitrógeno al cual están ambos unidos forman un anillo heterocíclico de 4 - 6 miembros; el anillo A y el anillo B se fusionan para formar un sistema anular policíclico, en donde el anillo A es un anillo heteroaromático de 5 miembros que tiene como sus únicos heteroátomos, ya sea (i) dos o tres átomos de nitrógeno, (ii) un átomo de nitrógeno y un átomo de oxígeno, o (iii) un átomo de nitrógeno y un átomo de azufre; en donde el anillo A está opcionalmente sustituido en un átomo de carbono por un sustituyente seleccionado del grupo que consiste en fluoro, cloro, metilo, y trifluorometilo; y el anillo B es un anillo carbocíclico de 4 a 8 miembros, o un anillo heterocíclico de 4 a 8 miembros que tiene de 1 a 3 heteroátomos seleccionados del grupo que consiste en nitrógeno, oxígeno y azufre; p es 1 ó 2, y q es 0 ó 1; o p es 0, y q es 1; en donde cuando p es 1, RB¹ es R³ᵃ y cuando p es 2, RB¹ es independientemente R³ᵃ y R³ᵇ y cada R³ᵃ y R³ᵇ, cuando están presentes, se seleccionan independientemente del grupo que consiste en halógeno, deutero, hidroxilo, alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, tioalquilo C₁₋₆, alquil C₁₋₆-N(R²)₂, y ciano; en donde dos sustituyentes alquilo C₁₋₆ pueden formar juntos un anillo puenteado o espirocíclico; y en donde si un átomo de nitrógeno en el anillo B está sustituido, el sustituyente no es halógeno, ciano, o un alcoxi C₁₋₆, haloalcoxi C₁₋₆ o tioalquilo C₁₋₆ que tiene un átomo de oxígeno o azufre unido directamente al átomo de nitrógeno; y en donde cuando q es 1, RB² es R⁴ y R⁴ se selecciona del grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, tioalquilo C₁₋₆, alquil C₁₋₆-N(R²)₂, fenilo, bencilo, CH₂-(cicloalquilo C₃₋₆), CH₂CH₂-(cicloalquilo C₃₋₆), CH₂-(heterociclilo de 4 a 6 miembros), CH₂CH₂-(heterociclilo de 4 a 6 miembros), heteroarilo de 5 a 6 miembros, y CH₂-(heteroarilo de 5 a 6 miembros); en donde cuando R⁴ es fenilo, heteroarilo o bencilo, el anillo fenilo o heteroarilo está opcionalmente sustituido por 1 a 3 sustituyentes seleccionados del grupo que consiste en halógeno, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄, y ciano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579392P | 2017-10-31 | 2017-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113811A1 true AR113811A1 (es) | 2020-06-10 |
Family
ID=64051580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103157A AR113811A1 (es) | 2017-10-31 | 2018-10-30 | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11072617B2 (es) |
| EP (1) | EP3704097B1 (es) |
| JP (1) | JP2021501183A (es) |
| KR (1) | KR20200083515A (es) |
| CN (1) | CN111278809B (es) |
| AR (1) | AR113811A1 (es) |
| AU (1) | AU2018360270A1 (es) |
| BR (1) | BR112020008446A2 (es) |
| CA (1) | CA3078688A1 (es) |
| CL (1) | CL2020001062A1 (es) |
| CO (1) | CO2020003475A2 (es) |
| CR (1) | CR20200168A (es) |
| IL (1) | IL273847A (es) |
| MA (1) | MA50503A (es) |
| MX (1) | MX2020003451A (es) |
| PE (1) | PE20211247A1 (es) |
| PH (1) | PH12020550537A1 (es) |
| RU (1) | RU2020115915A (es) |
| SG (1) | SG11202002877RA (es) |
| TW (1) | TW201922748A (es) |
| WO (1) | WO2019086494A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110282A1 (es) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| PT3652178T (pt) | 2017-07-14 | 2024-03-18 | H Hoffnabb La Roche Ag | Compostos bicíclicos de cetona e métodos de utilização dos mesmos |
| CR20200168A (es) | 2017-10-31 | 2020-07-12 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
| WO2020146615A1 (en) | 2019-01-11 | 2020-07-16 | Genentech, Inc. | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| WO2023083847A1 (en) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines as ripk1 inhibitors and use thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| WO1998056376A1 (en) * | 1997-06-13 | 1998-12-17 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
| CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1554572B1 (en) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7514441B2 (en) | 2002-08-26 | 2009-04-07 | Takeda Pharmaceutical Company Limited | Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents |
| US7220833B2 (en) | 2002-12-03 | 2007-05-22 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| ES2314418T3 (es) | 2003-05-02 | 2009-03-16 | Elan Pharmaceuticals, Inc. | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. |
| EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| BR112014010391A2 (pt) | 2011-11-03 | 2017-04-18 | Hoffmann La Roche | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica |
| CA2871695A1 (en) | 2012-05-22 | 2013-11-28 | F. Hoffmann-La Roche Ag | Substituted dipyridylamines and uses thereof |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| KR20160002850A (ko) | 2013-05-01 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 |
| PE20161063A1 (es) | 2013-05-01 | 2016-10-22 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos |
| CA2917198C (en) | 2013-07-10 | 2022-06-07 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| AU2015304851A1 (en) | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| CN107406462B (zh) | 2015-03-09 | 2020-11-10 | 豪夫迈·罗氏有限公司 | 三环dlk抑制剂及其用途 |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| JP6785252B2 (ja) | 2015-07-02 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式ラクタム及びその使用方法 |
| US10751444B2 (en) | 2015-08-07 | 2020-08-25 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MY196648A (en) * | 2016-02-05 | 2023-04-27 | Denali Therapeutics Inc | Inhibitors of Receptor-Interacting Protein Kinase 1 |
| WO2018089330A2 (en) | 2016-11-08 | 2018-05-17 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| AR110282A1 (es) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| PT3652178T (pt) | 2017-07-14 | 2024-03-18 | H Hoffnabb La Roche Ag | Compostos bicíclicos de cetona e métodos de utilização dos mesmos |
| MX2020003439A (es) | 2017-10-11 | 2020-07-29 | Hoffmann La Roche | Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1). |
| CR20200168A (es) | 2017-10-31 | 2020-07-12 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
-
2018
- 2018-10-30 CR CR20200168A patent/CR20200168A/es unknown
- 2018-10-30 AU AU2018360270A patent/AU2018360270A1/en not_active Abandoned
- 2018-10-30 MA MA050503A patent/MA50503A/fr unknown
- 2018-10-30 RU RU2020115915A patent/RU2020115915A/ru unknown
- 2018-10-30 EP EP18796020.8A patent/EP3704097B1/en active Active
- 2018-10-30 CN CN201880070578.0A patent/CN111278809B/zh active Active
- 2018-10-30 MX MX2020003451A patent/MX2020003451A/es unknown
- 2018-10-30 JP JP2020524177A patent/JP2021501183A/ja active Pending
- 2018-10-30 TW TW107138469A patent/TW201922748A/zh unknown
- 2018-10-30 CA CA3078688A patent/CA3078688A1/en active Pending
- 2018-10-30 WO PCT/EP2018/079772 patent/WO2019086494A1/en not_active Ceased
- 2018-10-30 AR ARP180103157A patent/AR113811A1/es unknown
- 2018-10-30 US US16/175,206 patent/US11072617B2/en active Active
- 2018-10-30 PE PE2020000353A patent/PE20211247A1/es unknown
- 2018-10-30 SG SG11202002877RA patent/SG11202002877RA/en unknown
- 2018-10-30 KR KR1020207015138A patent/KR20200083515A/ko not_active Ceased
- 2018-10-30 BR BR112020008446-8A patent/BR112020008446A2/pt not_active Application Discontinuation
-
2020
- 2020-03-25 CO CONC2020/0003475A patent/CO2020003475A2/es unknown
- 2020-04-06 IL IL273847A patent/IL273847A/en unknown
- 2020-04-20 CL CL2020001062A patent/CL2020001062A1/es unknown
- 2020-04-30 PH PH12020550537A patent/PH12020550537A1/en unknown
-
2021
- 2021-06-06 US US17/340,082 patent/US12338241B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111278809B (zh) | 2024-06-25 |
| RU2020115915A3 (es) | 2022-05-06 |
| BR112020008446A2 (pt) | 2020-12-29 |
| US11072617B2 (en) | 2021-07-27 |
| SG11202002877RA (en) | 2020-04-29 |
| MX2020003451A (es) | 2020-08-03 |
| JP2021501183A (ja) | 2021-01-14 |
| MA50503A (fr) | 2020-09-09 |
| US20190127382A1 (en) | 2019-05-02 |
| US20230002391A1 (en) | 2023-01-05 |
| IL273847A (en) | 2020-05-31 |
| WO2019086494A1 (en) | 2019-05-09 |
| KR20200083515A (ko) | 2020-07-08 |
| EP3704097B1 (en) | 2023-10-25 |
| CN111278809A (zh) | 2020-06-12 |
| AU2018360270A1 (en) | 2020-03-26 |
| PE20211247A1 (es) | 2021-07-13 |
| US12338241B2 (en) | 2025-06-24 |
| CR20200168A (es) | 2020-07-12 |
| TW201922748A (zh) | 2019-06-16 |
| CL2020001062A1 (es) | 2020-08-21 |
| EP3704097C0 (en) | 2023-10-25 |
| RU2020115915A (ru) | 2021-12-01 |
| EP3704097A1 (en) | 2020-09-09 |
| CA3078688A1 (en) | 2019-05-09 |
| PH12020550537A1 (en) | 2021-03-22 |
| CO2020003475A2 (es) | 2020-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113811A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR101586A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| ES2682398T3 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR105991A1 (es) | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR097252A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR102079A1 (es) | DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS b2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |